Advances in human antiglomerular basement membrane disease

Nature Reviews Nephrology

Volumn 7, Issue 12, 2011, Pages 697-705

  Cui, Zhao ^a   Zhao, Ming Hui ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 4; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EPITOPE; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; HLA DR ANTIGEN;

AGE DISTRIBUTION; ANEMIA; ANTIBODY TITER; B LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL FEATURE; DISEASE COURSE; FEVER; GENETIC ASSOCIATION; GENETIC LINKAGE; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; HEMATURIA; HEMOPTYSIS; HUMAN; HUMORAL IMMUNITY; HYPERTENSION; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LUNG HEMORRHAGE; MALAISE; NEPHROTIC SYNDROME; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REVIEW; SEX RATIO; T LYMPHOCYTE; WEIGHT REDUCTION;

ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; AUTOANTIBODIES; AUTOANTIGENS; BASEMENT MEMBRANE; GLOMERULAR BASEMENT MEMBRANE; HUMANS; IMMUNITY, CELLULAR; KIDNEY GLOMERULUS;

EID: 82355173382     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.89     Document Type: Review

References (106)

1. Stanton, M. C. & Tange, J. D. Goodpasture's syndrome (pulmonary haemorrhage associated with glomerulonephritis). Australas. Ann. Med. 7, 132-144 (1958).
2. Lerner, R. A., Glassock, R. J. & Dixon, F. J. The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis. J. Exp. Med. 126, 989-1004 (1967).
3. Sado, Y. et al. Induction of anti-GBM nephritis in rats by recombinant α3(IV)NC1 and α4(IV)NC1 of type IV collagen. Kidney Int. 53, 664-671 (1998). (Pubitemid 28124281)
4. Chen, L., Hellmark, T., Wieslander, J. & Bolton, W. K. Immunodominant epitopes of α3(IV)NC1 induce autoimmune glomerulonephritis in rats. Kidney Int. 64, 2108-2120 (2003). (Pubitemid 37449545)
5. Chen, L. et al. A nephritogenic peptide induces intermolecular epitope spreading on collagen IV in experimental autoimmune glomerulonephritis. J. Am. Soc. Nephrol. 17, 3076-3081 (2006). (Pubitemid 44707768)
6. Wu, J. et al. Glomerulonephritis induced by recombinant collagen IV alpha 3 chain noncollagen domain 1 is not associated with glomerular basement membrane antibody: a potential T cell-mediated mechanism. J. Immunol. 167, 2388-2395 (2001). (Pubitemid 32747554)
7. Robertson, J. et al. Activation of glomerular basement membrane-specific B cells in the renal draining lymph node after T cell-mediated glomerular injury. J. Am. Soc. Nephrol. 16, 3256-3263 (2005). (Pubitemid 46179331)
8. Wu, J. et al. A self T cell epitope induces autoantibody response: mechanism for production of antibodies to diverse glomerular basement membrane antigens. J. Immunol. 172, 4567-4574 (2004). (Pubitemid 38375274)
9. Arends, J. et al. T cell epitope mimicry in antiglomerular basement membrane disease. J. Immunol. 176, 1252-1258 (2006). (Pubitemid 43099730)
10. Wu, J. et al. T-cell epitope of α3 chain of type IV collagen induces severe glomerulonephritis. Kidney Int. 64, 1292-1301 (2003). (Pubitemid 37153794)
11. Holdsworth, S. R., Kitching, A. R. & Tipping, P. G. Th1 and Th2 T helper cell subsets affect patterns of injury and outcomes in glomerulonephritis. Kidney Int. 55, 1198-1216 (1999). (Pubitemid 29157116)
12. Phoon, R. K. et al. T-bet deficiency attenuates renal injury in experimental crescentic glomerulonephritis. J. Am. Soc. Nephrol. 19, 477-485 (2008). (Pubitemid 351355391)
13. Hopfer, H. et al. The importance of cell-mediated immunity in the course and severity of autoimmune anti-glomerular basement membrane disease in mice. FASAB J. 17, 860-868 (2003). (Pubitemid 36538661)
14. Summers, S. A. et al. Th1 and Th17 cells induce proliferative glomerulonephritis. J. Am. Soc. Nephrol. 20, 2518-2524 (2009).
15. Ooi, J. D., Phoon, R. K., Holdsworth, S. R. & Kitching, A. R. IL-23, not IL-12, directs autoimmunity to the Goodpasture antigen. J. Am. Soc. Nephrol. 20, 980-989 (2009).
16. Yang, R. et al. Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes. Nephrol. Dial. Transplant. 25, 2479-2486 (2010).
17. Mesnard, L. et al. Invariant natural killer T cells and TGF-beta attenuate anti-GBM glomerulonephritis. J. Am. Soc. Nephrol. 20, 1282-1292 (2009).
18. Reynolds, J. et al. Nasal administration of recombinant rat α3(IV)NC1 prevents the development of experimental autoimmune glomerulonephritis in the WKY rat. J. Am. Soc. Nephrol. 16, 1350-1359 (2005). (Pubitemid 41716519)
19. Reynolds, J., Khan, S. B., Allen, A. R., Benjamin, C. D. & Pusey, C. D. Blockade of the CD154-CD40 costimulatory pathway prevents the development of experimental autoimmune glomerulonephritis. Kidney Int. 66, 1444-1452 (2004). (Pubitemid 39298376)
20. Duncan, D. A., Drummond, K. N., Michael, A. F. & Vernier, R. L. pulmonary hemorrhage and glomerulonephritis. report of six cases and study of the renal lesion by the fluorescent antibody technique and electron microscopy. Ann. Intern. Med. 62, 920-938 (1965).
21. Pusey, C. D. Anti-glomerular basement membrane disease. Kidney Int. 64, 1535-1550 (2003). (Pubitemid 37153829)
22. Kluth, D. C. & Rees, A. J. Anti-glomerular basement membrane disease. J. Am. Soc. Nephrol. 10, 2446-2453 (1999). (Pubitemid 29501480)
23. Nachman, P. H., Jennette, J. C. & Falk, R. J. in Brenner and Rector's The Kidney 8th edn Vol. 1 Sec. V Ch. 30 (Brenner, B. M.) 1038-1042 (Saunders, Philadelphia, PA, USA, 2007).
24. Hirayama, K., Yamagata, K., Kobayashi, M. & Koyama, A. Anti-glomerular basement membrane antibody disease in Japan: part of the nationwide rapidly progressive glomerulonephritis survey in Japan. Clin. Exp. Nephrol. 12, 339-347 (2008).
25. Li, F. K. et al. Incidence and outcome of antiglomerular basement membrane disease in Chinese. Nephrology (Carlton) 9, 100-104 (2004). (Pubitemid 38530453)
26. Cui, Z., Zhao, M. H., Xin, G. & Wang, H. Y. Characteristics and prognosis of Chinese patients with anti-glomerular basement membrane disease. Nephron Clin. Pract. 99, c49-c55 (2005). (Pubitemid 40187049)
27. Savage, C. O., Pusey, C. D., Bowman, C., Rees, A. J. & Lockwood, C. M. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. Br. Med. J. (Clin. Res. Ed.) 292, 301-304 (1986). (Pubitemid 16144622)
28. Herody, M., Bobrie, G., Gouarin, C., Grunfeld, J. P. & Noel, L. H. Anti-GBM disease: predictive value of clinical, histological and serological data. Clin. Nephrol. 40, 249-255 (1993). (Pubitemid 23333355)
29. Segelmark, M., Hellmark, T. & Wieslander, J. The prognostic significance in Goodpasture's disease of specificity, titre and affinity of anti-glomerular-basement-membrane antibodies. Nephron Clin. Pract. 94, c59-c68 (2003).
30. Fischer, E. G. & Lager, D. J. Anti-glomerular basement membrane glomerulonephritis: a morphologic study of 80 cases. Am. J. Clin. Pathol. 125, 445-450 (2006). (Pubitemid 43327716)
31. Fisher, M., Pusey, C. D., Vaughan, R. W. & Rees, A. J. Susceptibility to anti-glomerular basement membrane disease is strongly associated with HLA-DRB1 genes. Kidney Int. 51, 222-229 (1997). (Pubitemid 27064541)
32. Phelps, R. G. & Rees, A. J. The HLA complex in Goodpasture's disease: a model for analyzing susceptibility to autoimmunity. Kidney Int. 56, 1638-1653 (1999). (Pubitemid 29518164)
33. Kitagawa, W. et al. The HLA-DRB1*1501 allele is prevalent among Japanese patients with anti-glomerular basement membrane antibody-mediated disease. Nephrol. Dial. Transplant. 23, 3126-3129 (2008).
34. Yang, R., Cui, Z., Zhao, J. & Zhao, M. H. The role of HLA-DRB1 alleles on susceptibility of Chinese patients with anti-GBM disease. Clin. Immunol. 133, 245-250 (2009).
35. Appel, G. B., Radhakrishnan, J. & D'Agati, V. in Brenner and Rector's The Kidney 8th edn Vol. 1 Sec. V Ch. 31 (Brenner, B. M.) 1097-1100 (Saunders, Philadelphia, PA, USA, 2007).
36. Donaghy, M. & Rees, A. J. Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet 2, 1390-1393 (1983).
37. Stevenson, A., Yaqoob, M., Mason, H., Pai, P. & Bell, G. M. Biochemical markers of basement membrane disturbances and occupational exposure to hydrocarbons and mixed solvents. QJM 88, 23-28 (1995).
38. Cui, Z. et al. Concurrent antiglomerular basement membrane disease and immune complex glomerulonephritis. Ren. Fail. 28, 7-14 (2006). (Pubitemid 43247284)
39. Hellmark, T., Niles, J. L., Collins, A. B., McCluskey, R. T. & Brunmark, C. Comparison of anti-GBM antibodies in sera with or without ANCA. J. Am. Soc. Nephrol. 8, 376-385 (1997). (Pubitemid 127454173)
40. Levy, J. B., Hammad, T., Coulthart, A., Dougan, T. & Pusey, C. D. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 66, 1535-1540 (2004). (Pubitemid 39298387)
41. Zhao, J. et al. Characteristics and outcome of Chinese patients with both antineutrophil cytoplasmic antibody and antiglomerular basement membrane antibodies. Nephron Clin. Pract. 107, c56-c62 (2007). (Pubitemid 47557269)
42. Rutgers, A. et al. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am. J. Kidney Dis. 46, 253-262 (2005). (Pubitemid 41040353)
43. O'Connor, K., Fulcher, D. & Phoon, R. K. Development of anti-glomerular basement membrane disease after remission from perinuclear ANCA-associated glomerulonephritis in a patient with HLA susceptibility. Am. J. Kidney Dis. 55, 566-569 (2010).
44. Wilson, C. B. & Dixon, F. J. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int. 3, 74-89 (1973).
45. Lin, W., Chen, M., Cui, Z. & Zhao, M. H. The immunopathological spectrum of crescentic glomerulonephritis: a survey of 106 patients in a single Chinese center. Nephron Clin. Pract. 116, c65-c74 (2010).
46. Couser, W. G. Rapidly progressive glomerulonephritis: classification, pathogenetic mechanisms, and therapy. Am. J. Kidney Dis. 11, 449-464 (1988).
47. Cui, Z., Zhao, J., Jia, X. Y., Zhu, S. N. & Zhao, M. H. Clinical features and outcomes of anti-glomerular basement membrane disease in older patients. Am. J. Kidney Dis. 57, 575-582 (2011).
48. Ang, C. et al. Anti-glomerular basement membrane (GBM)-antibody-mediated disease with normal renal function. Nephrol. Dial. Transplant. 13, 935-939 (1998). (Pubitemid 28161767)
49. Cui, Z., Zhao, M. H., Singh, A. K. & Wang, H. Y. Antiglomerular basement membrane disease with normal renal function. Kidney Int. 72, 1403-1408 (2007). (Pubitemid 350126772)
50. Ewan, P. W., Jones, H. A., Rhodes, C. G. & Hughes, J. M. Detection of intrapulmonary hemorrhage with carbon monoxide uptake. Application in goodpasture's syndrome. N. Engl. J. Med. 295, 1391-1396 (1976). (Pubitemid 8004132)
51. Cui, Z. et al. Outcomes of Chinese patients with anti-glomerular basement membrane disease receiving different therapeutic regimens: a large cohort study from a single center. Medicine (Baltimore) (in press).
52. Sinico, R. A., Radice, A., Corace, C., Sabadini, E. & Bollini, B. Anti-glomerular basement membrane antibodies in the diagnosis of Goodpasture syndrome: a comparison of different assays. Nephrol. Dial. Transplant. 21, 397-401 (2006). (Pubitemid 43159994)
53. Salama, A. D. et al. Goodpasture's disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques. Am. J. Kidney Dis. 39, 1162-1167 (2002). (Pubitemid 34591930)
54. Hudson, B. G., Tryggvason, K., Sundaramoorthy, M. & Neilson, E. G. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N. Engl. J. Med. 348, 2543-2556 (2003). (Pubitemid 36706542)
55. Abrahamson, D. R., Hudson, B. G., Stroganova, L., Borza, D. B. & St John, P. L. Cellular origins of type IV collagen networks in developing glomeruli. J. Am. Soc. Nephrol. 20, 1471-1479 (2009).
56. Borza, D. B. et al. Goodpasture autoantibodies unmask cryptic epitopes by selectively dissociating autoantigen complexes lacking structural reinforcement: novel mechanisms for immune privilege and autoimmune pathogenesis. J. Biol. Chem. 280, 27147-27154 (2005).
57. Vanacore, R. M. et al. A role for collagen IV cross-links in conferring immune privilege to the Goodpasture autoantigen: structural basis for the crypticity of B cell epitopes. J. Biol. Chem. 283, 22737-22748 (2008).
58. Vanacore, R. et al. A sulfilimine bond identified in collagen IV. Science 325, 1230-1234 (2009).
59. Yoshioka, K. et al. Identification of Goodpasture antigens in human alveolar basement membrane. Clin. Exp. Immunol. 74, 419-424 (1988).
60. Kalluri, R. et al. Identification of the α3 chain of type IV collagen as the common autoantigen in antibasement membrane disease and Goodpasture syndrome. J. Am. Soc. Nephrol. 6, 1178-1185 (1995).
61. Saus, J., Wieslander, J., Langeveld, J. P., Quinones, S. & Hudson, B. G. Identification of the Goodpasture antigen as the α3(IV) chain of collagen IV. J. Biol. Chem. 263, 13374-13380 (1988).
62. Pedchenko, V. et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N. Engl. J. Med. 363, 343-354 (2010).
63. Netzer, K. O. et al. The goodpasture autoantigen. Mapping the major conformational epitope(s) of α3(IV) collagen to residues 17-31 and 127-141 of the NC1 domain. J. Biol. Chem. 274, 11267-11274 (1999).
64. Borza, D. B. et al. Quaternary organization of the goodpasture autoantigen, the α3(IV) collagen chain. Sequestration of two cryptic autoepitopes by intrapromoter interactions with the α4 and α5 NC1 domains. J. Biol. Chem. 277, 40075-40083 (2002).
65. David, M., Borza, D. B., Leinonen, A., Belmont, J. M. & Hudson, B. G. Hydrophobic amino acid residues are critical for the immunodominant epitope of the Goodpasture autoantigen. A molecular basis for the cryptic nature of the epitope. J. Biol. Chem. 276, 6370-6377 (2001).
66. Kalluri, R., Cantley, L. G., Kerjaschki, D. & Neilson, E. G. Reactive oxygen species expose cryptic epitopes associated with autoimmune goodpasture syndrome. J. Biol. Chem. 275, 20027-20032 (2000). (Pubitemid 30441611)
67. Ghohestani, R. F. et al. Crescentic glomerulonephritis and subepidermal blisters with autoantibodies to alpha5 and alpha6 chains of type IV collagen. Lab. Invest. 83, 605-611 (2003). (Pubitemid 36618039)
68. Ghohestani, R. F., Hudson, B. G., Claudy, A. & Uitto, J. The α5 chain of type IV collagen is the target of IgG autoantibodies in a novel autoimmune disease with subepidermal blisters and renal insufficiency. J. Biol. Chem. 275, 16002-16006 (2000). (Pubitemid 30366905)
69. Kalluri, R. et al. Anti-α1(IV) collagen autoantibodies associated with lung adenocarcinoma presenting as the Goodpasture syndrome. Ann. Intern. Med. 124, 651-653 (1996). (Pubitemid 26103839)
70. Zhao, J. et al. Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity. Kidney Int. 76, 1108-1115 (2009).
71. Yang, R. et al. Antigen and epitope specificity of anti-glomerular basement membrane antibodies in patients with goodpasture disease with or without anti-neutrophil cytoplasmic antibodies. J. Am. Soc. Nephrol. 18, 1338-1343 (2007). (Pubitemid 46536921)
72. Dehan, P. et al. Sera from patients with anti-GBM nephritis including goodpasture syndrome show heterogenous reactivity to recombinant NC1 domain of type IV collagen α chains. Nephrol. Dial. Transplant. 11, 2215-2222 (1996). (Pubitemid 26385917)
73. Hellmark, T., Johansson, C. & Wieslander, J. Characterization of anti-GBM antibodies involved in Goodpasture's syndrome. Kidney Int. 46, 823-829 (1994). (Pubitemid 24272041)
74. Johansson, C., Butkowski, R., Swedenborg, P., Alm, P. & Wieslander, J. Characterization of a non-Goodpasture autoantibody to type IV collagen. Nephrol. Dial. Transplant. 8, 1205-1210 (1993). (Pubitemid 23342652)
75. Hellmark, T. et al. Identification of a clinically relevant immunodominant region of collagen IV in Goodpasture disease. Kidney Int. 55, 936-944 (1999). (Pubitemid 29100705)
76. Yang, R. et al. Levels of epitope-specific autoantibodies correlate with renal damage in anti-GBM disease. Nephrol. Dial. Transplant. 24, 1838-1844 (2009).
77. Levy, J. B., Turner, A. N., Rees, A. J. & Pusey, C. D. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann. Intern. Med. 134, 1033-1042 (2001). (Pubitemid 32488657)
78. Jindal, K. K. Management of idiopathic crescentic and diffuse proliferative glomerulonephritis: evidence-based recommendations. Kidney Int. Suppl. 70, S33-40 (1999).
79. Lockwood, C. M., Boulton-Jones, J. M., Lowenthal, R. M., Simpson, I. J. & Peters, D. K. Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis. Br. Med. J. 2, 252-254 (1975).
80. Cui, Z., Wang, H. Y. & Zhao, M. H. Natural autoantibodies against glomerular basement membrane exist in normal human sera. Kidney Int. 69, 894-899 (2006).
81. Coutinho, A., Kazatchkine, M. D. & Avrameas, S. Natural autoantibodies. Curr. Opin. Immunol. 7, 812-818 (1995). (Pubitemid 26038522)
82. Hayakawa, K. et al. Positive selection of natural autoreactive B cells. Science 285, 113-116 (1999). (Pubitemid 29307578)
83. Kazatchkine, M. D. & Kaveri, S. V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345, 747-755 (2001).
84. Yang, R. et al. Natural anti-GBM antibodies from normal human sera recognize α3(IV)NC1 restrictively and recognize the same epitopes as anti-GBM antibodies from patients with anti-GBM disease. Clin. Immunol. 124, 207-212 (2007). (Pubitemid 47064520)
85. Salama, A. D., Levy, J. B., Lightstone, L. & Pusey, C. D. Goodpasture's disease. Lancet 358, 917-920 (2001). (Pubitemid 32900581)
86. Cui, Z. & Zhao, M. H. Avidity of anti-glomerular basement membrane autoantibodies was associated with disease severity. Clin. Immunol. 116, 77-82 (2005). (Pubitemid 40733585)
87. Rutgers, A. et al. High affinity of anti-GBM antibodies from Goodpasture and transplanted Alport patients to α3(IV)NC1 collagen. Kidney Int. 58, 115-122 (2000). (Pubitemid 30429855)
88. Zhao, J., Yan, Y., Cui, Z., Yang, R. & Zhao, M. H. The immunoglobulin G subclass distribution of anti-GBM autoantibodies against rHα3(IV)NC1 is associated with disease severity. Hum. Immunol. 70, 425-429 (2009).
89. Cui, Z., Zhao, M. H., Segelmark, M. & Hellmark, T. Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals. Kidney Int. 78, 590-597 (2010).
90. Wong, D., Phelps, R. G. & Turner, A. N. The Goodpasture antigen is expressed in the human thymus. Kidney Int. 60, 1777-1783 (2001). (Pubitemid 32999982)
91. Zou, J. et al. Healthy individuals have Goodpasture autoantigen-reactive T cells. J. Am. Soc. Nephrol. 19, 396-404 (2008). (Pubitemid 351240661)
92. Salama, A. D. et al. In Goodpasture's disease, CD4+ T cells escape thymic deletion and are reactive with the autoantigen α3(IV)NC1. J. Am. Soc. Nephrol. 12, 1908-1915 (2001). (Pubitemid 32801366)
93. Salama, A. D. et al. Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease. Kidney Int. 64, 1685-1694 (2003). (Pubitemid 37323697)
94. Nolasco, F. E. et al. Intraglomerular T cells and monocytes in nephritis: study with monoclonal antibodies. Kidney Int. 31, 1160-1166 (1987). (Pubitemid 17069100)
95. Hellmark, T., Brunmark, C., Trojnar, J. & Wieslander, J. Epitope mapping of anti-glomerular basement membrane (GBM) antibodies with synthetic peptides. Clin. Exp. Immunol. 105, 504-510 (1996). (Pubitemid 26297897)
96. Cairns, L. S. et al. The fine specificity and cytokine profile of T-helper cells responsive to the α3 chain of type IV collagen in Goodpasture's disease. J. Am. Soc. Nephrol. 14, 2801-2812 (2003). (Pubitemid 37305643)
97. Zou, J. et al. Presentation of the Goodpasture autoantigen requires proteolytic unlocking steps that destroy prominent T cell epitopes. J. Am. Soc. Nephrol. 18, 771-779 (2007). (Pubitemid 46434494)
98. Johnson, J. P., Whitman, W., Briggs, W. A. & Wilson, C. B. Plasmapheresis and immunosuppressive agents in antibasement membrane antibody-induced Goodpasture's syndrome. Am. J. Med. 64, 354-359 (1978). (Pubitemid 8287309)
99. Lionaki, S., Jennette, J. C. & Falk, R. J. Anti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) autoantibodies in necrotizing and crescentic glomerulonephritis. Semin. Immunopathol. 29, 459-474 (2007). (Pubitemid 350077264)
100. Kelly, P. T. & Haponik, E. F. Goodpasture syndrome: molecular and clinical advances. Medicine (Baltimore) 73, 171-185 (1994). (Pubitemid 24245107)
101. Daly, C., Conlon, P. J., Medwar, W. & Walshe, J. J. Characteristics and outcome of anti-glomerular basement membrane disease: a single-center experience. Ren. Fail. 18, 105-112 (1996). (Pubitemid 26073879)
102. Merkel, F., Pullig, O., Marx, M., Netzer, K. O. & Weber, M. Course and prognosis of anti-basement membrane antibody (anti-BM-Ab)-mediated disease: report of 35 cases. Nephrol. Dial. Transplant. 9, 372-376 (1994). (Pubitemid 24136268)
103. Johnson, J. P. et al. Therapy of anti-glomerular basement membrane antibody disease: analysis of prognostic significance of clinical, pathologic and treatment factors. Medicine (Baltimore) 64, 219-227 (1985). (Pubitemid 16247105)
104. Bell, D. D., Moffatt, S. L., Singer, M. & Munt, P. W. Antibasement membrane antibody disease without clinical evidence of renal disease. Am. Rev. Respir. Dis. 142, 234-237 (1990). (Pubitemid 20224608)
105. Zimmerman, S. W., Varanasi, U. R. & Hoff, B. Goodpasture's syndrome with normal renal function. Am. J. Med. 66, 163-171 (1979). (Pubitemid 9089840)
106. Min, S. A. et al. Goodpasture's syndrome with normal renal function. Nephrol. Dial. Transplant. 11, 2302-2305 (1996). (Pubitemid 26385932)